Navigating the Complexity of Infectious Disease Development
Infectious disease trials require careful planning around changing epidemiology, patient populations, site selection, and regional considerations. Novotech brings the experience and insight to help sponsors make informed decisions and execute studies effectively.
Expertise Where It Matters
- Access to experienced infectious disease teams with therapeutic and clinical expertise
- Local regulatory expertise in key infectious disease research markets
- Established relationships with key opinion leaders, investigators, and research networks
Built for Infectious Disease Complexity
- Support for complex infectious disease programs across diverse indications, therapeutic approaches, and patient populations
- Expertise across development stages, from first-in-class programs and novel mechanisms to large-scale vaccine studies
- Local teams in key infectious disease research markets to support study planning and execution
Global Clinical Trial Delivery
- Support for therapies, vaccines, and prevention programs throughout development
- Global delivery capabilities across Asia-Pacific, North America, and Europe
- Regional knowledge and regulatory expertise supporting regional and global infectious disease programs
Early Development
Through ApprovalGlobal Regulatory &
Operational SupportTherapies Reaching
PatientsQuality & Compliance
at Every StepScientific Excellence
& InnovationData Integrity &
Transparency
Our Infectious Disease Experience at a Glance
443
Infectious Diseases studies conducted
872
Investigators and key opinion leaders engaged
1499
Sites activated globally
49
Countries supporting clinical programs
32371
Patients enrolled
54
Indications supported
24
Vaccine studies
Our Infectious Diseases Advantage
Deep Infectious Disease Expertise
- Dedicated infectious disease leadership and therapeutic expertise.
- Experience across viral, bacterial, fungal, and emerging infectious diseases.
- Expertise supporting complex infectious disease study designs; pioneering umbrella designs, platform studies and accelerated dosing structures.
- Experience across small molecules, antibodies, vaccines, immunotherapies, RNA, cell and gene therapies.
Strategic Access to Key Research Markets
- Deep roots in regions that account for a significant share of global infectious disease clinical research activity.
- Access to diverse patient populations, specialist treatment centers, and established research networks.
- Recognized world leading CRO in Hepatitis B research, with 130+ projects supported.
Global Development and Regulatory Expertise
- Integrated delivery model supporting regional and global infectious disease programs.
- Track record supporting infectious disease programs from early development to registration and post-marketing studies.
- Global operational and regulatory expertise across major development markets.
Indication Experience
Hover over each indication to explore conditions studied
Blood and systemic infections Sepsis; Bacterial infections; Pyogenic bacterial infection; Staphylococcus aureus infection; Bacterial meningitis; Meningococcal disease; MRSA infection
Neurological infections Viral encephalitis; Bacterial meningitis; Meningitis; Meningococcal disease; Other encephalitis; Postherpetic polyneuropathy
Respiratory infections Human RSV infection; Whooping cough; Pneumonia; Viral pneumonia; Bronchitis; Acute bronchitis; Upper respiratory tract infection; Acute nasopharyngitis; Acute otitis media; Other respiratory infections
Maternal, neonatal and reproductive infections Vulvovaginal candidiasis; Chlamydia; Genital warts; Other reproductive tract infections
Sexually transmitted infections Chlamydia; Genital warts; Sexually transmitted infections; Other STIs
Skin and soft tissue infections Herpes simplex infection; Chickenpox; Shingles/Zoster; Mpox; Infectious viral skin disease; Skin lesions; Other skin and soft tissue infections
Parasitic infections Malaria; Hookworm disease; Schistosomiasis; Head lice; Other parasitic diseases
Fungal infections Candidiasis; Vulvovaginal candidiasis; Fungal infections; Invasive aspergillosis; Other invasive fungal infections
Vector-borne diseases Malaria; Dengue; Zika virus disease; Chikungunya virus infection; Yellow fever; Lassa fever; Other vector-borne diseases
Gastrointestinal infections Gastroenteritis; Enteritis due to Norovirus; Enterocolitis; Cholera; Other gastrointestinal infections
Bacterial infections Tuberculosis; Respiratory tuberculosis; Typhoid; Staphylococcus aureus infection; Group A streptococcal infection; Bacterial infection; Other bacterial infections
Liver infections Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Viral hepatitis complications; Other liver-associated infectious indications
Viral infections COVID-19; Influenza; HIV infection; Cytomegaloviral infection; Zika virus disease; Adenovirus infection; Varicella zoster virus infection; Human RSV infection; Other viral infections
Zoonotic infections Rabies; Ebola disease; Henipavirus encephalitis; Other zoonotic diseases
The Global Leader in Hepatitis Research
Our hepatitis experience spans a broad range of development programs, study settings, and therapeutic approaches.
Experience Across Hepatitis Treatment Modalities
Our experience includes interventional studies across NAs, RNAi, CpAMs, HBsAg release inhibitors, monoclonal antibodies, cccDNA inhibitors, immunomodulators, T-cell therapies, checkpoint inhibitors, vaccines, and advanced therapies.
Dedicated Expertise in Vaccine Development
The Vaccine Strategic Delivery Unit provides focused clinical and operational support for vaccine programs, bringing together specialists across functions and regions to address the specific demands of vaccine trials.
From study planning through execution, the team works to anticipate challenges, support efficient delivery, and maintain a consistent focus on study quality and the needs of sponsors, sites, and patients.
Emerging Infectious Disease Therapeutic Approaches
Infectious disease expertise and global operational capabilities support programs across a range of therapeutic and prevention approaches.
Vaccines
- Prophylactic vaccines
- Therapeutic vaccines
- Novel administration routes
- Pandemic preparedness programs
Antiviral Innovation
- Long-acting antivirals
- RNAi based therapies
- Gene Editors
- Epigenomic Silencers
Immune-Based Therapies
- Immune-modulating therapies
- Mono- and Poly-clonal antibodies
- Checkpoint inhibitors
- Cytokine and Antagonist Modulators
Expertise That Guides Infectious Disease Development
Our infectious disease leadership brings extensive therapeutic, clinical, and operational experience to help sponsors make informed development decisions and successfully execute trials across regions.







